Blood traps may reveal lupus kidney treatment success

NCT ID NCT07721857

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

Lupus nephritis is a serious kidney complication of lupus that can lead to kidney failure. This study investigates whether levels of neutrophil extracellular traps (NETs)—web-like structures released by immune cells—in the blood can predict how well patients respond to therapy. Researchers will measure NETs in 100 adults with active lupus nephritis before and six months after starting treatment. If NETs prove to be a reliable marker, they could help doctors personalize treatment and monitor disease activity more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Measurement of neutrophil extracellular traps (NETs) in blood samples
What this could lead to
If NETs levels reliably predict treatment response, doctors could tailor lupus nephritis therapy earlier and more precisely, potentially improving outcomes.
What could go wrong
This is an observational, biomarker-focused study—not a treatment trial. NETs may not prove to be a reliable predictor, and results may not change clinical practice immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS (LN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.